ALPIX — Pixium Vision SA Share News
0.000.00%
Last trade - 00:00- €0.52m
- €5.28m
- €1.96m
Brief: Pixium Vision: First Patient Implantation In PRIMAvera In Netherlands
Brief: Pixium Vision H1 Operating Loss Widens To EUR 6.1 Mln
Brief: Pixium Vision Expands Its Board Of Directors With Appointment Of Anja Krammer And August Moretti
Brief: Pixium Vision End-March Cash Position At EUR 10.4 Million
Brief: Pixium Vision Receives FDA Approval For Prima System Clinical Trial At Stanford University
Brief: Pixium Vision Is Evaluating Future Financing Options
Brief: Pixium Vision FY Net Loss Widens To 11.1 Million Euros
Brief: Pixium Vision Expects PRIMAvera Read-Out Around End-2023
Brief: Pixium Vision End-Sept Cash Position At 16.9 Mln Euros
Brief: Pixium Vision Announces Positive Long-Term Follow-Up Data For The Prima Implant
Brief: Pixium Vision: expansion of PRIMAvera European pivotal study at London's Moorfields Eye Hospital
Brief: Pixium Vision H1 Operating Loss Widens To EUR 4.8 Mln
Brief: Pixium Vision Announces A Capital Increase Of Around 8 Million Euros
Brief: Pixium Vision Appoints Offer Nonhoff As CFO
Brief: Pixium Vision Considers Nasdaq Listing
Brief: Pixium Vision End-March Cash Position Up At 9.7 Million Euros
Brief: Pixium Vision Announces First Patient Successful Implantation In Prima System Pivotal Trial Primavera
Brief: Pixium Vision Says Termination Of Business Combination With Second Sight Medical Products
Brief: Pixium Vision Updates On Communication with Second Sight Medical Products Regarding Potential Private Placement